Search results for "Anemia"

showing 10 items of 352 documents

Successful treatment of resistant thrombotic thrombocytopenic purpura/hemolytic uremic syndrome with autologous peripheral blood stem and progenitor …

1999

The first-line treatment of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS syndrome) induces a response and survival rate of approximately 85%, even if a considerable number of patients relapse; nevertheless, a number of these patients are resistant to conventional management. Immunoablation followed by stem cell transplantation has been shown to be capable of inducing remissions in a large spectrum of experimental autoimmune disorders. We report here the case of a 20-year-old male patient with the TTP-HUS syndrome who was resistant to conventional treatment and was transplanted with autologous immunoselected CD34+ PBPC after conditioning with cyclosphosphamide, anti…

AdultMaleHemolytic anemiaLymphocyteThrombotic thrombocytopenic purpuraAntigens CD34Transplantation AutologousPrednisonehemic and lymphatic diseasesHumansMedicineProgenitor cellSurvival rateTransplantationPurpura Thrombotic Thrombocytopenicbusiness.industryHematopoietic Stem Cell TransplantationHematologyHematopoietic Stem Cellsmedicine.diseaseTransplantationmedicine.anatomical_structureHemolytic-Uremic SyndromeImmunologyStem cellbusinessmedicine.drugBone Marrow Transplantation
researchProduct

Quantitative evaluation of oxidative stress status on peripheral blood in beta-thalassaemic patients by means of electron paramagnetic resonance spec…

2005

Summary High oxidative stress status (OSS) is known to be one of the most important factors determining cell injury and consequent organ damage in thalassaemic patients with secondary iron overload. Using an innovative hydroxylamine ‘radical probe’ capable of efficiently trapping majority of oxygen-radicals including superoxide we measured, by electron paramagnetic resonance (EPR) spectroscopy, OSS in peripheral blood of 38 thalassaemic patients compared with sex-/age-matched healthy controls. Thalassaemic patients showed sixfold higher EPR values of OSS than controls. Significantly higher EPR values of OSS were observed in those with a severe phenotype (thalassaemia major, transfusion-depe…

AdultMaleHemolytic anemiamedicine.medical_specialtyIron Overloadmedicine.disease_causelaw.inventionchemistry.chemical_compoundHydroxylaminelawInternal medicineOXIDATIVE STRESS STATUSmedicineHumansB-THALASSAEMIC PATIENTSElectron paramagnetic resonanceChelating AgentsAnalysis of VarianceHematologySuperoxidebeta-ThalassemiaElectron Spin Resonance SpectroscopyHYDROXYLAMINEHematologyCHELATING THERAPYmedicine.diseaseOxidative StressELECTRON PARAMAGNETIC RESONANCEEndocrinologyHemoglobinopathychemistryCase-Control StudiesImmunologyFemaleDeferiproneOxidative stressBritish Journal of Haematology
researchProduct

Serum and fecal pancreatic enzymes in beta-thalassemia major

1997

This study, using indirect tests, demonstrated that exocrine pancreatic function is impaired in a proportion of patients with beta-thalassemia major (TM), though this impairment is generally mild or moderate.Impaired structure and function of the exocrine pancreas has been reported in patients with Beta-thalassemia major.In this study we measured fecal fats and serum and fecal pancreatic enzymes in 30 patients (13 M, 17 F) with TM, mean age 22.1 yr (range 14-39) and compared them with those of a matched group of healthy controls. Results were correlated with age, serum ferritin, blood transfusion, and various nutritional parameters. Enzymes assays included: serum pancreatic amylase (PA), li…

AdultMaleHemolytic anemiamedicine.medical_specialtyPancreatic diseaseAdolescentHydrolasesGastroenterologyFatsPathogenesisFecesEndocrinologyInternal medicinemedicineChymotrypsinHumansTrypsinFeceschemistry.chemical_classificationPancreatic Elastasebusiness.industrybeta-ThalassemiaGastroenterologyBeta thalassemiaLipasemedicine.diseaseHemoglobinopathyEnzymeEndocrinologyOncologychemistryAmylasesExocrine Pancreatic InsufficiencyFemalebusinessPancreatic enzymesInternational Journal of Pancreatology
researchProduct

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-fi…

2017

Myelodysplastic syndromes are characterised by ineffective erythropoiesis. Luspatercept (ACE-536) is a novel fusion protein that blocks transforming growth factor beta (TGF β) superfamily inhibitors of erythropoiesis, giving rise to a promising new investigative therapy. We aimed to assess the safety and efficacy of luspatercept in patients with anaemia due to lower-risk myelodysplastic syndromes.In this phase 2, multicentre, open-label, dose-finding study (PACE-MDS), with long-term extension, eligible patients were aged 18 years or older, had International Prognostic Scoring System-defined low or intermediate 1 risk myelodysplastic syndromes or non-proliferative chronic myelomonocytic leuk…

AdultMaleIneffective erythropoiesismyalgiamedicine.medical_specialtyPediatricsTime FactorsMaximum Tolerated DoseAnemiaActivin Receptors Type IIRecombinant Fusion ProteinsKaplan-Meier EstimateLower riskmedicine.disease_causeRisk AssessmentSeverity of Illness IndexDisease-Free SurvivalDrug Administration Schedule03 medical and health sciences0302 clinical medicineGermanyInternal medicineSeverity of illnessmedicineHumansProspective StudiesProspective cohort studyAdverse effectAgedProportional Hazards ModelsDose-Response Relationship Drugbusiness.industryMyelodysplastic syndromesAnemiaMiddle AgedPrognosismedicine.diseaseSurvival AnalysisActivinsImmunoglobulin Fc FragmentsTreatment OutcomeOncologyMyelodysplastic Syndromes030220 oncology & carcinogenesisFemalemedicine.symptombusiness030215 immunologyThe Lancet Oncology
researchProduct

Metabolic Evaluation of 94 Patients 5 to 16 Years After Ileocecal Pouch (Mainz Pouch 1) Continent Urinary Diversion

2003

PURPOSE In continent urinary diversion metabolic disturbances may be encountered in long-term followup. We evaluated metabolic consequences in patients with a minimum followup of 5 years after Mainz pouch 1 urinary diversion.At our institution continent urinary diversion using the ileocecal segment was performed between 1983 and 1995 in 458 patients. A total of 94 patients with an ileocecal pouch for a minimum of 5 years were reevaluated for metabolic changes. Median followup was 9.0 years. Routine laboratory parameters, blood gas analysis, vitamin B12, vitamin D25, cross-laps, bone specific alkaline phosphatase, osteocalcin and propeptide of type I collagen were obtained. Bone density was …

AdultMalePhosphopeptidesmedicine.medical_specialtyBone diseaseBone densityUrologymedicine.medical_treatmentUrinary systemOsteocalcinOsteoporosisSodium CitratePostoperative ComplicationsCalcitriolBone DensityReference ValuesPotassium CitrateHumansMedicineCitratesMegaloblastic anemiaAgedbusiness.industryUrinary Reservoirs ContinentUrinary diversionMiddle AgedAlkaline Phosphatasemedicine.diseaseSurgeryVitamin B 12FemaleCollagenBlood Gas AnalysisPouchAcidosisEnergy MetabolismbusinessContinent Urinary DiversionProcollagenFollow-Up StudiesJournal of Urology
researchProduct

First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: A quality of life directed phase II randomiz…

2009

Abstract Background Quality of life (QoL) has gained greater importance in the management of metastatic non-small-cell lung cancer due to the palliative nature of treatment. Docetaxel (DCT) and cisplatin (CDDP) doublet has been reported to be associated to a better QoL than the weekly vinorelbine (VNR) and CDDP regimen. Recently a newer more tolerated schedule of the VNR/CDDP regimen has been published and is widely employed in medical practice. The impact of these regimens on patients' QoL as well as symptoms control and type and grading chemo-related side-effects has been compared prospectically. Methods Patients received CDDP 75mg/m 2 plus DCT 75mg/m 2 on day 1 every weeks (arm A) or CDD…

AdultMalePulmonary and Respiratory MedicineOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniamedicine.medical_treatmentDocetaxelNeutropeniaVinblastineVinorelbineClinical ProtocolsQuality of lifeCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerneoplasmsAgedChemotherapybusiness.industryAnemiaVinorelbineMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryRegimenOncologyDocetaxelDisease ProgressionQuality of LifeFemaleTaxoidsCisplatinbusinessFebrile neutropeniamedicine.drugLung Cancer
researchProduct

Risk of mortality from anemia and iron overload in nontransfusion-dependent β-thalassemia

2021

AdultMaleRiskPediatricsmedicine.medical_specialtyIron OverloadAnemiabusiness.industryThalassemiabeta-ThalassemiaAnemiaHematologyKaplan-Meier Estimatemedicine.diseaseYoung AdultTransfusion dependencemedicineRisk of mortalityHumansBlood TransfusionFemaleMortalitybusinessHuman
researchProduct

Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia

2013

Background and Objective Increased expression of fetal hemoglobin (HbF) may ameliorate the clinical course of hemoglobinopathies like sickle cell disease (SCD) and β-thalassemia. Hydroxyurea (HU) can stimulate HbF production in these diseases but the response is highly variable indicating the utility of developing an in vitro test to predict the patient's response to HU. We assessed whether the HbF response of patients with SCD and thalassemia intermedia (TI) to HU correlates with HBG (both γ-globin genes) expression in their cultured erythroid progenitors following exposure to HU. Patients and Methods We exposed primary erythroid cultures from peripheral blood mononuclear cells from 30 pat…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesCellPrimary Cell CultureGene ExpressionAnemia Sickle CellBiologyPeripheral blood mononuclear cellhydroxyurealiquid erythroid cultureYoung AdultIn vivohemic and lymphatic diseasesFetal hemoglobinmedicineHumansgamma-GlobinsRNA MessengerFetal HemoglobinAgedErythroid Precursor CellsMessenger RNAbeta-ThalassemiaBeta thalassemiaHematologyGeneral MedicineMiddle Agedmedicine.diseaseb-thalassemiaMolecular biologyReal-time polymerase chain reactionmedicine.anatomical_structureTreatment OutcomeCell cultureFemalesickle cell disease
researchProduct

Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience

2007

This study reports the first evaluation of therapeutic response in Romanian patients with Gaucher disease type I, after therapy with Cerezyme recently became available in our country.24 patients (11-50 years) received Cerezyme 20-60 U/kg every two weeks for at least 18 months. Haemoglobin, platelet count, volume of the liver and spleen, plasma chitotriosidase and the severity score were assessed every 6 months; skeletal radiography and osteodensitometry were also monitored.Eleven patients were splenectomized before start of therapy. Eight patients had anaemia (mean haemoglobin 9.4 g/dl) and 14 patients, of whom 13 were without splenectomy, had thrombocytopenia (mean 65,692/mm3). Haemoglobin…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyPediatricsTime FactorsAdolescentBone diseasemedicine.medical_treatmentDiseaseWeight GainSeverity of Illness IndexHemoglobinsGeneticsmedicineHumansIn patientChildGenetics (clinical)ChemotherapyGaucher DiseasePlatelet CountRomaniabusiness.industryLiver DiseasesRomaniannutritional and metabolic diseasesAnemiaEnzyme replacement therapyMiddle Agedmedicine.diseaseCombined Modality TherapyThrombocytopeniaRecombinant Proteinslanguage.human_languageSurgeryHexosaminidasesTreatment OutcomeSplenomegalyQuality of LifeSplenectomylanguageGlucosylceramidaseFemaleBone DiseasesbusinessFollow-Up StudiesJournal of Inherited Metabolic Disease
researchProduct

Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania

2008

Background Studies of antiretroviral therapy (ART) programs in Africa have shown high initial mortality. Factors contributing to this high mortality are poorly described. The aim of the present study was to assess mortality and to identify predictors of mortality in HIV-infected patients starting ART in a rural hospital in Tanzania. Methods This was a cohort study of 320 treatment-naïve adults who started ART between October 2003 and November 2006. Reliable CD4 cell counts were not available, thus ART initiation was based on clinical criteria in accordance with WHO and Tanzanian guidelines. Kaplan-Meier models were used to estimate mortality and Cox proportional hazards models to identify p…

AdultMalemedicine.medical_specialtyAdolescentAnemiaHospitals RuralHIV InfectionsKaplan-Meier EstimateTanzanialcsh:Infectious and parasitic diseasesCohort StudiesRisk FactorsInternal medicinemedicineHumanslcsh:RC109-216Survival analysis:Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin sosialmedisin: 801 [VDP]SurveillanceProportional hazards modelbusiness.industryHazard ratioMalnutritionAnemiaMiddle Agedmedicine.diseasePrognosisSurvival AnalysisThrombocytopenia:Medisinske Fag: 700::Helsefag: 800::Forebyggende medisin: 804 [VDP]SurgeryMalnutritionInfectious DiseasesAnti-Retroviral AgentsFemalebusinessRisk assessmentBody mass indexCohort studyFollow-Up StudiesResearch ArticleBMC Infectious Diseases
researchProduct